Merck’s PREVYMIS gets Health Canada’s approval for CMV disease prevention
Merck, referred as MSD outside the US and Canada, has confirmed that Health Canada has approved a new indication for PREVYMIS (letermovir) to prevent cytomegalovirus (CMV) disease in